BC Week In Review | Aug 19, 2013
Clinical News

Civacir: Phase III started

Biotest began the open-label, North American Phase III Study 988 to evaluate 200 and 300 mg/kg Civacir in up to 90 patients. Patients will receive Civacir starting on the day of liver transplant, but prior...
BC Innovations | Apr 19, 2012
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV envelope glycoproteins In vitro and mouse studies have identified mAbs binding to HCV envelope glycoproteins that could help treat or prevent infection....
BioCentury | Sep 17, 2007
Finance

Ebb & Flow

Investors who have followed Mark Levin's lead have rarely been disappointed. Thus it's no surprise that his new venture fund, Third Rock Ventures , raised $378 million in only 10 weeks on the road. Founded by...
BC Week In Review | Mar 19, 2007
Company News

Nabi renal, infectious, neurology news

The reorganization follows a strategic alternatives process that began last year (see BioCentury, Oct. 2, 2006). NABI hopes to complete the process by year end. At Dec. 31, 2006, the company had $86.2 million in...
BC Week In Review | Jan 22, 2007
Clinical News

Civacir: Phase II started

The companies began an open-label Phase II trial in 30 patients. Patients will receive 400 mg/kg of IV Civacir or standard care. Kedrion licensed European rights to the product last year (see BioCentury, July 3,...
BioCentury | Nov 6, 2006
Regulation

HCV immunotherapeutics

HCV immunotherapeutics HCV immunotherapeutics Selected HCV immunotherapeutics in clinical development and registration. (A) Marketed ex-U.S. for HBV, HCV and for use as a vaccine adjuvant; (B) Has ex-U.S rights from Boehringer. Conducting a Phase II...
BC Week In Review | Jul 3, 2006
Company News

Nabi, Kedrion S.p.A. deal

Kedrion received an exclusive license to commercialize NABI's Civacir in the EU. The polyclonal antibody is being developed to prevent recurrence of HCV-related liver disease in HCV-positive liver transplant recipients, or in patients who receive...
BC Week In Review | Feb 13, 2006
Clinical News

Civacir: Phase II start

NABI will begin in next half a double-blind, placebo-controlled, U.S. and European Phase II study in about 100 HCV patients who underwent liver transplant. About 25 patients in each group will receive either 100, 200...
BC Week In Review | Feb 6, 2006
Clinical News

Civacir regulatory update

FDA granted Fast Track designation to Civacir to prevent hepatitis C virus (HCV) re-infection in liver transplant patients. The HCV neutralizing polyclonal antibody has Orphan Drug designations in Europe and in the U.S. Nabi Biopharmaceuticals...
BioCentury | Nov 7, 2005
Product Development

Nabi chronicles

Nabi chronicles Last Tuesday's announcement that NABI was halting development of its StaphVax vaccine sent the stock into a freefall; it dropped $8.35 (71%) to $3.40 on the week. Additionally, NABI said it would halt...
Items per page:
1 - 10 of 19